Drug Profile
Colorectal cancer vaccine - Immune Response
Alternative Names: IR 705Latest Information Update: 24 Sep 2021
Price :
$50
*
At a glance
- Originator Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Colorectal cancer
Most Recent Events
- 08 Sep 2004 Immune Response Corporation has signed a license transfer agreement with NovaRx covering the technology in-licensed from the Sidney Kimmel Cancer Center
- 31 Dec 2003 Discontinued - Phase-I for Colorectal cancer in USA (unspecified route)
- 25 Jun 2002 This vaccine is still in active development